Business Description
2cureX AB
ISIN : SE0010468124
Compare
Compare
Traded in other countries / regions
2CUREX.Sweden2QE.Germany IPO Date
2017-11-24Description
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.83 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -4.42 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -30.1 | |||||
3-Year EPS without NRI Growth Rate | -35.5 | |||||
3-Year FCF Growth Rate | -33.5 | |||||
3-Year Book Growth Rate | 2.6 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 35.39 | |||||
9-Day RSI | 42.37 | |||||
14-Day RSI | 42.93 | |||||
6-1 Month Momentum % | -82.47 | |||||
12-1 Month Momentum % | -94.44 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.53 | |||||
Quick Ratio | 5.53 | |||||
Cash Ratio | 4.84 | |||||
Days Sales Outstanding | 4993.83 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.3 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -13441.37 | |||||
Net Margin % | -13257.03 | |||||
FCF Margin % | -11978.71 | |||||
ROE % | -94.59 | |||||
ROA % | -86.07 | |||||
ROIC % | -755.56 | |||||
ROC (Joel Greenblatt) % | -2341.97 | |||||
ROCE % | -89.14 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 20.67 | |||||
PB Ratio | 0.31 | |||||
Price-to-Tangible-Book | 0.31 | |||||
EV-to-EBIT | 0.41 | |||||
EV-to-Forward-EBIT | -7.96 | |||||
EV-to-EBITDA | 0.41 | |||||
EV-to-Revenue | -50.79 | |||||
EV-to-Forward-Revenue | 11.06 | |||||
EV-to-FCF | 0.42 | |||||
Price-to-Net-Current-Asset-Value | 0.32 | |||||
Price-to-Net-Cash | 0.38 | |||||
Earnings Yield (Greenblatt) % | 243.9 | |||||
FCF Yield % | -546.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
2cureX AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | 0.249 | ||
EPS (TTM) (kr) | -1.874 | ||
Beta | 0 | ||
Volatility % | 87.22 | ||
14-Day RSI | 42.93 | ||
14-Day ATR (kr) | 0.076532 | ||
20-Day SMA (kr) | 0.34045 | ||
12-1 Month Momentum % | -94.44 | ||
52-Week Range (kr) | 0.203 - 5.78 | ||
Shares Outstanding (Mil) | 17.6 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
2cureX AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
2cureX AB Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
2cureX AB Frequently Asked Questions
What is 2cureX AB(OSTO:2CUREX)'s stock price today?
The current price of OSTO:2CUREX is kr0.31. The 52 week high of OSTO:2CUREX is kr5.78 and 52 week low is kr0.20.
When is next earnings date of 2cureX AB(OSTO:2CUREX)?
The next earnings date of 2cureX AB(OSTO:2CUREX) is 2024-06-20.
Does 2cureX AB(OSTO:2CUREX) pay dividends? If so, how much?
2cureX AB(OSTO:2CUREX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |